China’s transgenic animal models provider Cyagen Biosciences has raised 285 million yuan ($41 million) from CMS Capital, Grower Venture Capital, GF Qianhe and GF Investment. In a separate development, Alibaba-backed Amwise has secured $10 million in its Series B round led by Simcere Medical Diagnosis.
Cyagen Biosciences snags $41m in Series B round
China’s transgenic animal models provider Cyagen Biosciences has secured 285 million yuan ($41 million) in a Series B round of financing from China Merchants Securities’ investment vehicle CMS Capital, Grower Venture Capital, GF Securities’ subsidiaries GF Qianhe and GF Investment, according to a company statement.
